Pharvaris (PHVS) Profit After Tax Growth (3y) (2023 - 2026)
Pharvaris (PHVS) Profit After Tax Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - | 9.53% |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn | -27.65% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 70.25% |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 47.10% |
| 10 | Pharvaris | 2.22 Bn | 1.94 Bn | - | -23.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.62% |
| Dec 31, 2025 | -10.81% |
| Sep 30, 2025 | -71.83% |
| Jun 30, 2025 | -56.36% |
| Mar 31, 2025 | -39.42% |
| Dec 31, 2024 | -25.99% |
| Sep 30, 2024 | -62.77% |
| Jun 30, 2024 | -20.49% |
| Mar 31, 2024 | -61.36% |
| Dec 31, 2023 | -40.88% |
| Sep 30, 2023 | -50.90% |
| Jun 30, 2023 | -55.61% |
| Mar 31, 2023 | -88.67% |